Journal of Lipid and Atherosclerosis最新文献_第6页

Risk Stratification of Cardiovascular Disease according to Age Groups in New Prevention Guidelines: A Review. 新预防指南中按年龄组划分的心血管疾病风险分层：综述。

Journal of Lipid and Atherosclerosis Pub Date : 2023-05-01 Epub Date: 2023-03-20 DOI: 10.12997/jla.2023.12.2.96

Kwang-Il Kim

{"title":"Risk Stratification of Cardiovascular Disease according to Age Groups in New Prevention Guidelines: A Review.","authors":"Kwang-Il Kim","doi":"10.12997/jla.2023.12.2.96","DOIUrl":"10.12997/jla.2023.12.2.96","url":null,"abstract":"Age is a strong risk factor for cardiovascular disease. Accordingly, most cardiovascular risk prediction models have included age as an independent risk factor. There is much evidence that effective management of cardiovascular risk factors improves clinical outcomes even in older adults. However, there are concerns that intensive treatment for older adults increases the risk of adverse events. For hypertensive patients, intensive blood pressure reduction with combination therapy increases the risk of syncope, acute kidney injury, and falls. Intensive glucose-lowering therapy among older patients with diabetes increases the risk of hypoglycemia or cognitive impairment. These findings suggest that a balanced approach for older adults is required to increase the benefits and decrease the risk of side effects. In contrast to older people, the estimated 10-year cardiovascular risk in young and healthy individuals is low. However, the lifetime cardiovascular risk in these patients is actually high. The 2021 European Society of Cardiology guideline on cardiovascular disease prevention in clinical practice has been published. It proposed a different risk stratification and recommendation for treatment according to age group, based on the concept of avoiding undertreatment in young people and overtreatment in older persons. Although the guideline recommends age-dependent risk stratification, risk categories should not be applied to the mandatory initiation of drug treatment. In all age groups, other factors such as lifetime cardiovascular risk, treatment benefit and harm, comorbidities, frailty, and patient preferences should be considered when managing patients for primary prevention.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 2","pages":"96-105"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/31/jla-12-96.PMC10232216.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9923669","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Benefits and Harms of COVID-19 Vaccines in Cardiovascular Disease: A Comprehensive Review. COVID-19疫苗在心血管疾病中的益处和危害:综合综述

Journal of Lipid and Atherosclerosis Pub Date : 2023-05-01 DOI: 10.12997/jla.2023.12.2.119

Chung-Yen Chen, Ta-Chen Su

{"title":"Benefits and Harms of COVID-19 Vaccines in Cardiovascular Disease: A Comprehensive Review.","authors":"Chung-Yen Chen, Ta-Chen Su","doi":"10.12997/jla.2023.12.2.119","DOIUrl":"https://doi.org/10.12997/jla.2023.12.2.119","url":null,"abstract":"Patients with a history of cardiovascular disease (CVD) who contract coronavirus disease 2019 (COVID-19) tend to have a worse prognosis and more severe cardiovascular side effects. COVID-19 vaccines, which are intended to prevent COVID-19, may also potentially reduce the severity and complications (including cardiovascular sequelae) of COVID-19, especially in patients with a history of CVD. However, there have also been reports of cardiovascular side effects from COVID-19 vaccines of various brands and types. The purpose of this study is to review the benefits and harms of COVID-19 vaccines in relation to CVD. In this thorough review of the most current evidence on the benefits and harms of COVID-19 vaccines, we present information about the characteristics of cardiovascular complications. Most of the evidence focuses on myocarditis or pericarditis, which are most strongly associated with mRNA vaccines and predominantly occur in young males within days of receiving the second dose. Meanwhile, post-vaccination myocardial infarction is more common in older males, and the first dose of adenoviral vector vaccines appears to play a greater role in this complication. This information may guide us in formulating alternative options and implementing targeted surveillance. Gaining more knowledge about the potential benefits and harms of COVID-19 vaccines will improve our ability to make informed decisions and judgments about the balance of these factors.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 2","pages":"119-131"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a8/4c/jla-12-119.PMC10232218.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9621358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single-Molecule Imaging of Membrane Proteins on Vascular Endothelial Cells. 血管内皮细胞膜蛋白的单分子成像。

Journal of Lipid and Atherosclerosis Pub Date : 2023-01-01 DOI: 10.12997/jla.2023.12.1.58

Jiseong Park, Siwoo Jin, Juhee Jang, Daeha Seo

引用次数: 1

Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement. 韩国 2 型糖尿病患者的血脂管理：韩国糖尿病协会和韩国血脂与动脉粥样硬化学会共识声明。

Journal of Lipid and Atherosclerosis Pub Date : 2023-01-01 Epub Date: 2023-01-17 DOI: 10.12997/jla.2023.12.1.12

Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon

{"title":"Lipid Management in Korean People With Type 2 Diabetes Mellitus: Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis Consensus Statement.","authors":"Ye Seul Yang, Hack-Lyoung Kim, Sang-Hyun Kim, Min Kyong Moon","doi":"10.12997/jla.2023.12.1.12","DOIUrl":"10.12997/jla.2023.12.1.12","url":null,"abstract":"Dyslipidemia in patients with diabetes is an important treatment target as a modifiable risk factor for cardiovascular disease (CVD). Although the primary treatment goal for dyslipidemia is to control low-density lipoprotein cholesterol (LDL-C), achieving this goal remains suboptimal according to recent studies. It is important to set the target goal for LDL-C control based on an accurate risk assessment for CVD. Here, we summarize the latest evidence on lipid management in patients with diabetes and present a consensus of the Korean Diabetes Association and Korean Society of Lipid and Atherosclerosis on the treatment goals of LDL-C according to the duration of diabetes, presence of CVD, target organ damage, or major cardiovascular risk factors. In patients with type 2 diabetes mellitus (T2DM) and CVD, an LDL-C goal of <55 mg/dL and a reduction in LDL-C level by 50% or more from the baseline is recommended. For the primary prevention of CVD in patients with T2DM with a duration of diabetes ≥10 years, major cardiovascular risk factors, or target organ damage, an LDL-C goal of <70 mg/dL is recommended. In patients with T2DM with a duration of diabetes <10 years and no major cardiovascular risk factors, an LDL-C goal of <100 mg/dL is recommended.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 1","pages":"12-22"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/15/bf/jla-12-12.PMC9884550.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10688893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Introduction to Umbrella Reviews as a Useful Evidence-Based Practice. 介绍伞式评论作为一种有用的循证实践。

Journal of Lipid and Atherosclerosis Pub Date : 2023-01-01 DOI: 10.12997/jla.2023.12.1.3

Geun Joo Choi, Hyun Kang

{"title":"Introduction to Umbrella Reviews as a Useful Evidence-Based Practice.","authors":"Geun Joo Choi, Hyun Kang","doi":"10.12997/jla.2023.12.1.3","DOIUrl":"https://doi.org/10.12997/jla.2023.12.1.3","url":null,"abstract":"The umbrella review (UR) is a novel methodological approach that has been established to address the ever-expanding research volume of published systematic reviews. In this study, we examined the rationale underlying URs, the concepts and goals of URs, and their applicability in clinical settings. Additionally, we briefly assessed the process of conducting URs and discussed the current challenges in this regard. URs are used to integrate, evaluate, and synthesize the findings of related systematic reviews. By organizing and summarizing the abundant information in accordance with the level of evidence, URs can serve as a useful methodological tool and provide appropriate entry points to clinicians or decision-makers in the medical field. Considering the availability of many suitable interventions for specific conditions in a broad field, URs can enable evidence-based decision-making and offer a broad perspective for the resolution of issues in healthcare by summarizing the evidence and providing directions on a variety of topics. URs are clearly contributing to the management of the deluge of evidence in evidence-based medicine. However, despite the availability of several directions for conducting URs, some points of confusion persist, especially when determining the certainty of evidence. Therefore, advanced guidelines for the appropriate performance of URs are required to provide more reliable evidence through URs.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 1","pages":"3-11"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/04/24/jla-12-3.PMC9884555.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10679264","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a). 治疗血脂异常2的新方法:LDL-C和Lp(a)。

Journal of Lipid and Atherosclerosis Pub Date : 2023-01-01 DOI: 10.12997/jla.2023.12.1.37

Kyung An Kim, Hun-Jun Park

{"title":"New Therapeutic Approaches to the Treatment of Dyslipidemia 2: LDL-C and Lp(a).","authors":"Kyung An Kim, Hun-Jun Park","doi":"10.12997/jla.2023.12.1.37","DOIUrl":"https://doi.org/10.12997/jla.2023.12.1.37","url":null,"abstract":"Dyslipidemia is an important risk factor for atherosclerotic cardiovascular disease (ASCVD). There are abundant and unequivocal data to indicate that low-density lipoproteins (LDL) are a cause of ASCVD. Reduction of plasma low-density lipoprotein cholesterol (LDL-C) by medical therapy such as statins, ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have proven to significantly reduce the risk of cardiovascular events. However, for many reasons, many patients are not able to achieve LDL-C levels recommended by guidelines on currently available therapies. This has led to the development of new drugs lowering LDL-C, such as inclisiran, bempedoic acid, and evinacumab, in the hope of reducing cardiovascular (CV) risk. Drugs targeting lipoprotein (a) (Lp[a]) also have a role in the prevention of atherosclerosis, with genetic studies having established that 20%-30% of the human population inherits plasma Lp(a) levels in the atherogenic range. In this paper, we will review the recent progress made in the approaches to LDL-C and Lp(a) therapeutic modulation.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 1","pages":"37-46"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/86/e9/jla-12-37.PMC9884549.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10679266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6

Evaluation of the Paradoxical Association Between Lipid Levels and Incident Atrial Fibrillation According to Statin Usage: A Nationwide Cohort Study. 根据他汀类药物的使用评估血脂水平和房颤发生率之间的矛盾关系:一项全国性队列研究。

Journal of Lipid and Atherosclerosis Pub Date : 2023-01-01 DOI: 10.12997/jla.2023.12.1.73

Hyo-Jeong Ahn, So-Ryoung Lee, Eue-Keun Choi, Seung-Woo Lee, Kyung-Do Han, Soonil Kwon, Seil Oh, Gregory Y H Lip

{"title":"Evaluation of the Paradoxical Association Between Lipid Levels and Incident Atrial Fibrillation According to Statin Usage: A Nationwide Cohort Study.","authors":"Hyo-Jeong Ahn, So-Ryoung Lee, Eue-Keun Choi, Seung-Woo Lee, Kyung-Do Han, Soonil Kwon, Seil Oh, Gregory Y H Lip","doi":"10.12997/jla.2023.12.1.73","DOIUrl":"https://doi.org/10.12997/jla.2023.12.1.73","url":null,"abstract":"Objective: Higher levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) are associated with a lower risk of atrial fibrillation (AF). Statin use might exert confounding effects on the paradoxical associations; however, the relationships that distinguish statin users from non-users have not been thoroughly evaluated.Methods: From the Korean National Health Insurance Database, we included 9,778,014 adults who underwent a health examination in 2009. The levels of TC and LDL-C at the health examination were categorized into quartile values of the total study population. We grouped the study population into statin users and non-users and investigated the associations between TC, LDL-C, and the risk of incident AF.Results: Of the total population, 867,336 (8.9%) were taking statins. During a mean follow-up of 8.2 years, inverse associations of TC - AF and LDL-C - AF were observed; higher levels of TC and LDL-C were associated with the lower risk of AF in the total population. Overall, statin users showed higher AF incidence rate than non-users, but the inverse associations of TC - AF and LDL-C - AF were consistently observed irrespective of statin usage; adjusted hazard ratio with 95% confidence interval was 0.81 (0.79-0.84) for statin users and 0.81 (0.80-0.83) for non-users in the highest TC quartile, and 0.84 (0.82-0.87) for statin users and 0.85 (0.84-0.86) for non-users in the highest LDL-C quartile (all p<0.001).Conclusion: The paradoxical relationship between lipid levels (TC and LDL-C) and the risk of AF remains consistent in both statin users and non-users.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 1","pages":"73-86"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/62/19/jla-12-73.PMC9884554.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10679265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Journal Metrics and Statistics. 期刊计量与统计。

Journal of Lipid and Atherosclerosis Pub Date : 2023-01-01 DOI: 10.12997/jla.2023.12.1.87

Hyun Kang

引用次数: 0

New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3. 治疗1型血脂异常的新方法:ApoC-III和ANGPTL3。

Journal of Lipid and Atherosclerosis Pub Date : 2023-01-01 DOI: 10.12997/jla.2023.12.1.23

Ji Yoon Kim, Nam Hoon Kim

{"title":"New Therapeutic Approaches to the Treatment of Dyslipidemia 1: ApoC-III and ANGPTL3.","authors":"Ji Yoon Kim, Nam Hoon Kim","doi":"10.12997/jla.2023.12.1.23","DOIUrl":"https://doi.org/10.12997/jla.2023.12.1.23","url":null,"abstract":"Low-density lipoprotein cholesterol (LDL-C)-lowering therapy that increases LDL receptor expression in several ways robustly reduces the risk of atherosclerotic cardiovascular disease (CVD). However, a substantial risk of CVD still remains after intensive LDL-C reduction, which requires new treatment modalities for dyslipidemia and cardiovascular risk management. Triglycerides (TGs) and triglyceride-rich lipoproteins (TRLs) have received attention as indicators of residual cardiovascular risk and as direct causal factors for atherosclerosis and CVDs. Advances in understanding TG and TRL metabolism and their association with clinically evident CVDs have led to the development of novel therapeutic targets, including apolipoprotein C-III (apoC-III) and angiopoietin-like protein 3 (ANGPTL3). Genetic association studies have indicated that both apoC-III and ANGPTL3 play a causal role in the development of atherosclerotic CVD. Both molecules contribute to lipid dysregulation and atherosclerosis primarily by inhibiting lipoprotein lipase; however, recent evidence has shown that novel pathways exist in relation to their lipid-modifying activities. Notably, recent progress in therapeutic approaches, such as monoclonal antibodies or antisense oligonucleotides, has led to several novel therapeutics targeting apoC-III and ANGPTL3. This review summarized the recent updates and discussions related to apoC-III and ANGPTL3 expression.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 1","pages":"23-36"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/b0/jla-12-23.PMC9884553.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10679267","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

Pyruvate Dehydrogenase Complex and Glucose Oxidation as a Therapeutic Target in Diabetic Heart Disease. 丙酮酸脱氢酶复合物和葡萄糖氧化作为糖尿病性心脏病的治疗靶点。

Journal of Lipid and Atherosclerosis Pub Date : 2023-01-01 DOI: 10.12997/jla.2023.12.1.47

Seyed Amirhossein Tabatabaei Dakhili, Amanda A Greenwell, John R Ussher

{"title":"Pyruvate Dehydrogenase Complex and Glucose Oxidation as a Therapeutic Target in Diabetic Heart Disease.","authors":"Seyed Amirhossein Tabatabaei Dakhili, Amanda A Greenwell, John R Ussher","doi":"10.12997/jla.2023.12.1.47","DOIUrl":"https://doi.org/10.12997/jla.2023.12.1.47","url":null,"abstract":"Diabetic cardiomyopathy was originally described as the presence of ventricular dysfunction in the absence of coronary artery disease and/or hypertension. It is characterized by diastolic dysfunction and is more prevalent in people with diabetes than originally realized, leading to the suggestion in the field that it simply be referred to as diabetic heart disease. While there are currently no approved therapies for diabetic heart disease, a multitude of studies clearly demonstrate that it is characterized by several disturbances in myocardial energy metabolism. One of the most prominent changes in myocardial energy metabolism in diabetes is a robust impairment in glucose oxidation. Herein we will describe the mechanisms responsible for the diabetes-induced decline in myocardial glucose oxidation, and the pharmacological approaches that have been pursued to correct this metabolic disorder. With surmounting evidence that stimulating myocardial glucose oxidation can alleviate diastolic dysfunction and other pathologies associated with diabetic heart disease, this may also represent a novel strategy for decreasing the prevalence of heart failure with preserved ejection fraction in the diabetic population.","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 1","pages":"47-57"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e9/01/jla-12-47.PMC9884548.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10688898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1